BioInvent International (BINV) Corporate presentation summary

Pipeline and clinical programs

• Two lead antibodies, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcyRIIB), have demonstrated clinical proof of concept in ovarian cancer, NSCLC, CTCL, uveal melanoma, and NHL.

• BI-1808 shows single-agent activity and durable responses in ovarian cancer and CTCL, with potential to become a new standard of care.

• BI-1206 targets resistance mechanisms in follicular lymphoma and solid tumors, showing significant efficacy in combination regimens.

• Multiple Phase 2a readouts are expected in mid-2026 for both programs, with pivotal studies planned for 2027.

• Complete and partial responses have been observed across all clinical programs.

BI-1808 (anti-TNFR2) highlights

• Demonstrates a differentiated mechanism by depleting regulatory T cells, activating myeloid cells, and expanding CD8+ T cells.

• In ovarian cancer, BI-1808 plus pembrolizumab achieved a 24% ORR and 57% DCR, with durable responses and manageable safety profile.

• In CTCL, monotherapy showed a 46% ORR and 92% DCR, with early immune activation and favorable safety.

• Potential blockbuster opportunity in ovarian cancer and CTCL, addressing large, underserved markets.

• Planned data releases in 2026 include Phase 2a updates for both monotherapy and combination regimens.

BI-1206 (anti-FcyRIIB) highlights

• Blocks a key resistance pathway to antibody therapies, resensitizing tumors to CD20 therapy in follicular lymphoma.

• In combination with rituximab, BI-1206 achieved a 59% ORR and 41% CRR in follicular lymphoma, with long-lasting responses.

• Triplet therapy (BI-1206 + rituximab + acalabrutinib) showed an 80% ORR and 100% DCR in NHL, with good tolerability.

• In solid tumors, BI-1206 plus pembrolizumab demonstrated durable responses in anti-PD-1 refractory melanoma and uveal melanoma.

• Ongoing Phase 2a studies in NSCLC and uveal melanoma, with first data expected in H2 2026.